Italy Antibody Drug Conjugates Market Size & Outlook
Italy antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
Italy antibody drug conjugates market highlights
- The Italy antibody drug conjugates market generated a revenue of USD 154.3 million in 2021 and is expected to reach USD 758.8 million by 2030.
- The Italy market is expected to grow at a CAGR of 19.4% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 154.3 million |
| Market revenue in 2030 | USD 758.8 million |
| Growth rate | 19.4% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Italy accounted for 2.7% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 758.8 million by 2030.
Breast cancer was the largest segment with a revenue share of 70.64% in 2021. Horizon Databook has segmented the Italy antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Bureaucratic hurdles in the approval of new drugs and the high cost of new drugs are often cited by the Italian Association for Medical Oncology, even though the country’s National Health Service is known for reimbursing ADC drugs such as Kadcyla.
Kadcyla, Adectris, Besponsa, and Mylotarg are some of the ADCs currently available on the market. The approval of new ADCs, coupled with the growing incidence of various target indications, is expected to drive the market during the forecast period.
For instance, in May 2021, Mediterranea Theranostic Srl, an Italian biopharmaceutical firm, licensed its anti-Trop2 (tumor associated calcium signal transducer) to Lego Chem for ADC use through a contract after joint research over two years.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Italy antibody drug conjugates market size, by application, 2018-2030 (US$M)
Italy Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
